医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Dr. Reddy’s Announces the Launch of PRAMIPEXOLE Dihydrochloride Extended-Release Tablets

2015年08月12日 PM10:35
このエントリーをはてなブックマークに追加


 

HYDERABAD, India

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched PRAMIPEXOLE dihydrochloride extended-release tablets 0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg, a therapeutic equivalent generic version of MIRAPEX ER® (pramipexole dihydrochloride) Extended-Release Tablets in the US market on August 11, 2015, following the approval by the United States Food & Drug Administration (USFDA).

The MIRAPEX ER® brand and generic had U.S. sales of approximately $48.3 Million MAT for the most recent twelve months ending in June 2015 according to IMS Health*.

Dr. Reddy’s PRAMIPEXOLE dihydrochloride extended-release tablets mg are available in 0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg in bottle count sizes of 30.

MIRAPEX ER is a registered trademark of Boehringer Ingelheim Pharma GmbH & Co. KG CORPORATION FED REP GERMANY
*IMS National Sales Perspectives: Retail and Non-Retail MAT June 2015

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infectives. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, Russia & CIS, Venezuela and India. For more information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganisation, including related integration issues.

The company assumes no obligation to update any information contained herein.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150812005749/en/

CONTACT

Dr. Reddy’s Laboratories Ltd.
INVESTOR RELATIONS
Kedar
Upadhye, kedaru@drreddys.com
Ph:
+91-40-66834297
or
MEDIA RELATIONS
Calvin Printer, calvinprinter@drreddys.com
Ph:
+91-40-49002121

同じカテゴリーの記事 

  • InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
  • METIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長
  • Poxel to Report Its 2023 Annual Results by the End of April 2024
  • Kolmar Korea Wins Case Against Italian Cosmetics Maker Intercos for Suncare Technology Theft
  • 大手CDMOのPCIファーマ・サービシズが初の包括ESG報告書を発表